On the Rheology of Red Blood Cell Suspensions with Different
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The National Drugs List
^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ. -
Effect of Intake of Food Hydrocolloids of Bacterial Origin on the Glycemic Response in Humans: Systematic Review and Narrative Synthesis
nutrients Review Effect of Intake of Food Hydrocolloids of Bacterial Origin on the Glycemic Response in Humans: Systematic Review and Narrative Synthesis Norah A. Alshammari 1,2, Moira A. Taylor 3, Rebecca Stevenson 4 , Ourania Gouseti 5, Jaber Alyami 6 , Syahrizal Muttakin 7,8, Serafim Bakalis 5, Alison Lovegrove 9, Guruprasad P. Aithal 2 and Luca Marciani 2,* 1 Department of Clinical Nutrition, College of Applied Medical Sciences, Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia; [email protected] 2 Translational Medical Sciences and National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Nottingham NG7 2UH, UK; [email protected] 3 Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, Queen’s Medical Centre, National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham NG7 2UH, UK; [email protected] 4 Precision Imaging Beacon, University of Nottingham, Nottingham NG7 2UH, UK; [email protected] 5 Department of Food Science, University of Copenhagen, DK-1958 Copenhagen, Denmark; [email protected] (O.G.); [email protected] (S.B.) 6 Department of Diagnostic Radiology, Faculty of Applied Medical Science, King Abdulaziz University (KAU), Jeddah 21589, Saudi Arabia; [email protected] 7 Indonesian Agency for Agricultural Research and Development, Jakarta 12540, Indonesia; Citation: Alshammari, N.A.; [email protected] Taylor, M.A.; Stevenson, R.; 8 School of Chemical Engineering, University of Birmingham, Birmingham B15 2TT, UK Gouseti, O.; Alyami, J.; Muttakin, S.; 9 Rothamsted Research, Harpenden, Hertfordshire AL5 2JQ, UK; [email protected] Bakalis, S.; Lovegrove, A.; Aithal, G.P.; * Correspondence: [email protected]; Tel.: +44-115-823-1248 Marciani, L. -
Differential Effects of the Poly (ADP-Ribose)Polymerase (PARP
British Journal of Cancer (2001) 84(1), 106–112 © 2001 Cancer Research Campaign doi: 10.1054/ bjoc.2000.1555, available online at http://www.idealibrary.com on http://www.bjcancer.com Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro KJ Bowman*, DR Newell, AH Calvert and NJ Curtin Cancer Research Unit, University of Newcastle upon Tyne Medical School, Framlington Place, Newcastle upon Tyne NE2 4HH, UK Summary The potent novel poly(ADP-ribose) polymerase (PARP) inhibitor, NU1025, enhances the cytotoxicity of DNA-methylating agents and ionizing radiation by inhibiting DNA repair. We report here an investigation of the role of PARP in the cellular responses to inhibitors of topoisomerase I and II using NU1025. The cytotoxicity of the topoisomerase I inhibitor, camptothecin, was increased 2.6-fold in L1210 cells by co-incubation with NU1025. Camptothecin-induced DNA strand breaks were also increased 2.5-fold by NU1025 and exposure to camptothecin-activated PARP. In contrast, NU1025 did not increase the DNA strand breakage or cytotoxicity caused by the topoisomerase II inhibitor etoposide. Exposure to etoposide did not activate PARP even at concentrations that caused significant levels of apoptosis. Taken together, these data suggest that potentiation of camptothecin cytotoxicity by NU1025 is a direct result of increased DNA strand breakage, and that activation of PARP by camptothecin-induced DNA damage contributes to its repair and consequently cell survival. However, in L1210 cells at least, it would appear that PARP is not involved in the cellular response to etoposide-mediated DNA damage. -
(12) Patent Application Publication (10) Pub. No.: US 2012/0028333 A1 Piatesi Et Al
US 20120028333A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0028333 A1 Piatesi et al. (43) Pub. Date: Feb. 2, 2012 (54) USE OF ENZYMES TO REDUCE ALDEHYDES (30) Foreign Application Priority Data FROMALDEHYDE-CONTAINING PRODUCTS Apr. 7, 2009 (EP) .................................. O9157522.5 Publication Classification (76) Inventors: Andrea Piatesi, Mannheim (DE); (51) Int. Cl. Tilo Habicher, Speyer (DE); CI2N 9/02 (2006.01) Michael Bischel, Worms (DE); CI2N I/00 (2006.01) Li-Wen Wang, Mannheim (DE): CI2N 15/63 (2006.01) Jirgen Reichert, Limburgerhof A62D 3/02 (2007.01) (DE); Rainer Packe-Wirth, C7H 2L/04 (2006.01) Trostberg (DE); Kai-Uwe (52) U.S. Cl. ... 435/189: 435/262:536/23.2:435/320.1; Baldenius, Heidelberg (DE); Erich 435/243 Kromm, Weisenheim am Sand (57) ABSTRACT (DE); Stefan Häfner, Speyer (DE); Carsten Schwalb. Mannheim (DE); The invention relates to the use of an enzyme preparation Hans Wolfgang Höffken, which catalyzes the degradation of formaldehyde for reduc Ludwigshafen (DE) ing the formaldehyde content in a formaldehyde-containing formulation. In a preferred embodiment, the enzyme prepa ration contains a formaldehyde dismutase from a Pseudomo (21) Appl. No.: 13/262,662 nas putida Strain. Further, the invention refers to a process for reducing the formaldehyde content in cross-linking agents for textile finishing or in polymer dispersions used, e.g. in con (22) PCT Filed: Mar. 31, 2010 struction chemistry. Further the invention relates to the use of an enzyme preparation which catalyzes the degradation of (86). PCT No.: PCT/EP1OAS4284 aldehydes for reducing the formaldehyde content in an alde hyde-containing formulation. -
(Haemagel) Versus 6% Hydroxyethyl Starch 200/0.5 (Haes-Steril) for Plasma Volume Expansion in Critically-Ill Patients Magdy Ali Omera, MD* , Salah A
Alexandria Journal of Anaesthesia and Intensive Care 44 Autoclaved Gelatin (Haemagel) Versus 6% Hydroxyethyl Starch 200/0.5 (Haes-steril) For Plasma Volume Expansion In Critically-ill Patients Magdy Ali Omera, MD* , Salah A. Ismail, MD* * Assistant Prof. of Anaesthesia, Faculty of Medicine, Suez Canal University. ABSTRACT Synthetic colloids are used to optimize hemodynamics in the critically ill patients and a debate about the most suitable one is still present. The influence of short term infusion of autoclaved gelatin (Haemagel) and 6% hydroxyethyl starch 200/0.5 (Haes-steril) on hemodynamic, respiratory, coagulation, renal and oncotic parameters were examined in a prospective randomized study. Method: Thirty patients suffering from systemic hypoperfusion due to sepsis in ICU of Suez Canal University Hospital were assigned into 2 equal groups. In GEL group: 1000 ml of Haemagel was infused within an hour, while in HES group: 1000 ml of 6% Haes-steril 200/0.5 was given within an hour. The hemodynamic, respiratory, hematological, coagulation, renal and colloidal osmotic pressure parameters were recorded before and after infusion of both colloids. Results: There was a significant similar increase in hemodynamic variables (Mean arterial pressure, central venous pressure, cardiac index, stroke volume index and left ventricular stroke work index) in both groups. Also, a significant improvement in tissue perfusion as judged by decreased arterial lactate was found. There were no significant differences in any of the measured respiratory parameters (respiratory rate, arterial oxygen saturation, arterial blood gases and intrapulmonary shunt) in the studied groups. No significant intergroup difference in any haemodynamic or respiratory variable was demonstrated. -
Clinical Pharmacology of Infusion Fluids
Clinical pharmacology of infusion fluids Robert G. Hahn Linköping University Post Print N.B.: When citing this work, cite the original article. Original Publication: Robert G. Hahn , Clinical pharmacology of infusion fluids, 2012, Acta Medica Lituanica, (19), 3. Licencee: Lithuanian Academy of Sciences http://www.lmaleidykla.lt/ojs/index.php/actamedicalituanica/index Postprint available at: Linköping University Electronic Press http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-91319 ACTA MEDICA LITUANICA. 2012. Vol. 19. No. 3. P. 210–212 © Lietuvos mokslų akademija, 2012 Clinical pharmacology of infusion fluids Robert G. Hahn Fluids are used for intravenous infusion during practically all surgeries, but several different compositions are available on the market. Södertälje Hospital, Crystalloid fluids comprise lactated or acetated Ringer solutions, nor- Södertälje, Sweden; mal saline, Plasma-Lyte, hypertonic saline, and glucose. They lack allergic Anaesthesia and properties but are prone to cause peripheral tissue oedema. Their turn- Intensive Care, over is governed by physiological factors such as dehydration and drug Linköping University, effects. Sweden Colloid fluids include hydroxyethyl starch, albumin, dextran, and gela- tin. These fluids have various degrees of allergic properties and do not promote peripheral oedema. Their half-life is usually about hours. Factors increasing the turnover rate are poorly known but might include inflam- matory states. Current debates include the widespread use of normal saline, which should be replaced by Ringer’s or Plasma-Lyte in most situations, and the kidney damage associated with the use of starch in septic patients. New studies show that hypertonic saline does not improve survival or neuro- logical damage in prehospital care. -
Selection of Cryoprotectant in Lyophilization of Progesterone-Loaded Stearic Acid Solid Lipid Nanoparticles
pharmaceutics Article Selection of Cryoprotectant in Lyophilization of Progesterone-Loaded Stearic Acid Solid Lipid Nanoparticles Timothy M. Amis, Jwala Renukuntla, Pradeep Kumar Bolla and Bradley A. Clark * Department of Basic Pharmaceutical Sciences, Fred Wilson School of Pharmacy, High Point University, High Point, NC 27268, USA; [email protected] (T.M.A.); [email protected] (J.R.); [email protected] (P.K.B.) * Correspondence: [email protected]; Tel.: +1-336-841-9665 Received: 18 August 2020; Accepted: 16 September 2020; Published: 19 September 2020 Abstract: Cryoprotectants are often required in lyophilization to reduce or eliminate agglomeration of solute or suspended materials. The aim of this study was to select a cryoprotecting agent and optimize its concentration in a solid lipid nanoparticle formulation. Progesterone-loaded stearic acid solid lipid nanoparticles (SA-P SLNs) were prepared by hot homogenization with high speed mixing and sonication. The stearic acid content was 4.6% w/w and progesterone was 0.46% w/w of the initial formulation. Multiple surfactants were evaluated, and a lecithin and sodium taurocholate system was chosen. Three concentrations of surfactant were then evaluated, and a concentration of 2% w/w was chosen based on particle size, polydispersity, and zeta potential. Agglomeration of SA-P SLNs after lyophilization was observed as measured by increased particle size. Dextran, glycine, mannitol, polyvinylpyrrolidone (PVP), sorbitol, and trehalose were evaluated as cryoprotectants by both an initial freeze–thaw analysis and after lyophilization. Once selected as the cryoprotectant, trehalose was evaluated at 5%, 10%, 15%, and 20% for optimal concentration, with 20% trehalose being finally selected as the level of choice. -
6) Dextran Antibody → Behavior of an Anti
Position Effects of Variable Region Carbohydrate on the Affinity and In Vivo Behavior of an Anti-(1→6) Dextran Antibody This information is current as M. Josefina Coloma, Ryan K. Trinh, Alexander R. Martinez of September 27, 2021. and Sherie L. Morrison J Immunol 1999; 162:2162-2170; ; http://www.jimmunol.org/content/162/4/2162 Downloaded from References This article cites 45 articles, 14 of which you can access for free at: http://www.jimmunol.org/content/162/4/2162.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 27, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 1999 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Position Effects of Variable Region Carbohydrate on the Affinity and In Vivo Behavior of an Anti-(136) Dextran Antibody1 M. Josefina Coloma, Ryan K. Trinh, Alexander R. Martinez, and Sherie L. Morrison2 IgG is a glycoprotein with an N-linked carbohydrate structure attached to the CH2 domain of each of its heavy chains. -
Coagulation Effects of Mannitol in Combination with 0.9% Normal Saline Or Hydroxyethyl Starch in Patients Undergoing Supratentorial Craniotomy: a Preliminary Report
Original Article Coagulation effects of mannitol in combination with 0.9% normal saline or hydroxyethyl starch in patients undergoing supratentorial craniotomy: A preliminary report Hemanshu Prabhakar, Gyaninder Pal Singh, Parmod Kumar Bithal, Mani Kalaivani1 Abstract Background: Neurosurgical patients often require administration of both, mannitol and hydroxyethyl starch (HES). A recent in vitro study demonstrated that HES in combination with mannitol could disturb coagulation parameters and should be avoided in neurosurgical practice. The aim of our study was to evaluate coagulation abnormalities due to mannitol when administered alone and in combination with HES in patients undergoing craniotomy for various intracranial brain tumours. Materials and Methods: We enrolled 30 adult patients undergoing craniotomy. Patients were randomised into two groups using a computer generated randomisation chart. Interventions: Group A: Patients received 10 ml/kg 0.9% normal saline and 1 g/kg mannitol and Group B: Patients received 10 ml/kg, HES 130/0.4, and 1 gm/kg mannitol; immediately after induction of general anaesthesia. Rotational thromboelastography was done immediately after induction of general anaesthesia and 5 min after administration of mannitol. Measured parameters of blood coagulation were clotting time (CT) and clot formation time (CFT) with EXTEM and maximum clot firmness (MCF) with EXTEM and (FIBTEM). Results: Fourteen patients in each group completed the study. Insignificant change was noted in CT; CFT altered significantly from the baseline in both the groups (P < 0.05). MCF with FIBTEM did not change significantly from baseline (P > 0.05), but significantly differed between groups (P = 0.001). However, all values were in normal range. -
Physical Charaterization of Red Blood Cell Aggregation Daniel Amadeus Dominic Flormann
Physical charaterization of red blood cell aggregation Daniel Amadeus Dominic Flormann To cite this version: Daniel Amadeus Dominic Flormann. Physical charaterization of red blood cell aggregation. Biological Physics [physics.bio-ph]. Universität des Saarlandes, 2017. English. NNT : 2017GREAY002. tel- 01577838 HAL Id: tel-01577838 https://tel.archives-ouvertes.fr/tel-01577838 Submitted on 28 Aug 2017 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. THÈSE Pour obtenir le grade de DOCTEUR DE LA COMMUNAUTÉ UNIVERSITÉ GRENOBLE ALPES préparée dans le cadre d’une cotutelle entre la Communauté Université Grenoble Alpes et l’Universität des Saarlandes Spécialité : Physique pour les sciences du vivant Arrêté ministériel : 25 mai 2016 Présentée par Daniel Amadeus Dominic Flormann Thèse dirigée par M. Thomas Podgorski et M. Christian Wagner préparée au sein du Laboratoire Interdisciplinaire de Physique, Grenoble et de Experimentalphysik, Saarbrücken dans les Écoles doctorales de Physique de l’Université Grenoble Alpes et de Dekanat der Universität des Saarlandes -
Hypertonic Saline (7.2%) in 6% Hydroxyethyl Starch Reduces Intracranial Pressure and Improves Hemodynamics in a Placebo-Controll
Continuing Medical Education Article Hypertonic saline (7.2%) in 6% hydroxyethyl starch reduces intracranial pressure and improves hemodynamics in a placebo-controlled study involving stable patients with subarachnoid hemorrhage* Gunnar Bentsen, MD; Harald Breivik, MD, DMSc, FRCA; Tryggve Lundar, MD, DMSc; Audun Stubhaug, MD, DMSc LEARNING OBJECTIVES On completion of this article, the reader should be able to: 1. Describe the effects of hypertonic saline (7.2% saline in 6% hydroxyethyl starch 200/0.5) on intracranial pressure. 2. Compare the effects of hypertonic with normal saline on cerebral perfusion pressure. 3. Use this information in a clinical setting. All authors have disclosed that they have no financial relationships with or interests in any commercial companies pertaining to this educational activity. Lippincott CME Institute, Inc., has identified and resolved all faculty conflicts of interest regarding this educational activity. Visit the Critical Care Medicine Web site (www.ccmjournal.org) for information on obtaining continuing medical education credit. Objective: To compare the effects of a bolus infusion of hyper- was ؊5.6 (range, ؊0.8 to ؊12.2) mm Hg after 64 (range, 40 to tonic saline hydroxyethyl starch with the effects of normal saline 115) mins. Mean difference in cerebral perfusion pressure change placebo) on intracranial pressure (ICP) and cerebral perfusion pres- between the groups (HSS ؊ normal saline) was 5.4 mm Hg (95%) and mean difference in ,(002. ؍ sure in patients with spontaneous subarachnoid hemorrhage. confidence interval, 2.2 to 8.6; p Design and Setting: Prospective, randomized, single-blinded, cardiac index change, measured as the area under the curve for placebo-controlled study in a university hospital. -
United States Patent (19) 11 Patent Number: 5,723,281 Segall Et Al
US005723281A United States Patent (19) 11 Patent Number: 5,723,281 Segall et al. 45 Date of Patent: Mar. 3, 1998 54 PLASMA-LIKE SUBSTANCE Fischer et al. "Flush Solution 2. A New Concept for One -to-Three Day Hypothermic Renal Storage Preservation” 75) Inventors: Paul E. Segall; Harold D. Waitz: Hal Transplantation (1985) 39(2):122-126. Sternberg; Judith M. Segall, all of Kallerhoff et al., "Effects of Preservation Conditions and Berkeley, Calif. Temperature on Tissue Acidification in Canine Kidneys" Transplantation (1985) 39(5):485-489. 73) Assignee: BioTime, Inc., Berkeley, Calif. Ross et al. "72-HR Canine Kidney Preservation Without Continuous Perfusion' Transplantation (1976) (21) Appl. No.: 471,396 21(6):498-501. (22 Filed: Jun. 6, 1995 Sprung et al., "Effects of Acute Hypothermia and b-Adren ergic Receptor Blockade on Serum Potassium Concentration Related U.S. Application Data in Rats' Critical Care Medicine (1991), 19(12):1545-51. Wall et al., "Simple Hypothermic Preservation for Trans 60 Division of Ser. No. 133,527, Oct. 7, 1993, abandoned, which is a continuation-in-part of Ser. No. 71533, Jun, 4, porting Human Livers Long Distances for Transplantation” 1993, Pat. No. 5,407,428. Transplantation (1977) 23(3):210-216. (51) Int. Cl. ................. A01N 1/00; A61K 31/715; Primary Examiner-Leon B. Lankford, Jr. A61K 31/72: A61K 47/36 Assistant Examiner-Francisco C. Prats 52 U.S. Cl. ............................ 435/12; 435/1.1; 435/1.3; Attorney, Agent, or Firm-Karl Bozicevic; Bozicevic & 514/54; 514/59; 514/60; 424/717 Reed, LLP; Bret Field 58) Field of Search ..............................